Who Qualifies for Statins Under the 2026 Guidelines?

If you are trying to answer “Do I qualify for a statin under the new guidelines?”, start with the part that does not require a calculator. Under the 2026 ACC/AHA multisociety dyslipidemia guideline, some people qualify because of an existing condition or cholesterol level; others qualify because their estimated PREVENT cardiovascular risk crosses a treatment threshold.

The important first split is automatic qualification versus risk-score qualification. Existing ASCVD, LDL-C of at least 190 mg/dL, diabetes at ages 40-75, CKD stage 3 or higher, and HIV at ages 40-75 are risk-independent criteria in the 2026 guideline; the PREVENT calculator is not used to decide whether those groups qualify in the first place. [1]

The First Gate: Do You Qualify Without a Risk Score?

A risk calculator is useful only after the obvious indications have been checked. Someone who has already had atherosclerotic cardiovascular disease, such as a heart attack, ischemic stroke, or symptomatic peripheral artery disease, is being treated to prevent another event. That is a different clinical problem from estimating the first event in an otherwise undiagnosed person.

LDL-C of 190 mg/dL or higher is another bypass lane. The same is true for adults ages 40-75 with diabetes, adults with CKD stage 3 or higher, and adults ages 40-75 with HIV. These are not “maybe if your score is high enough” groups; the guideline treats them as high-enough-risk categories before the calculator enters the conversation. [1]

That matters in ordinary lab-result situations. A 58-year-old with diabetes does not need a 10-year risk estimate to learn whether the guideline recommends statin therapy. A 42-year-old without diabetes, CKD, HIV, ASCVD, or LDL-C of 190 mg/dL or higher does need the risk-score pathway.

The Calculator Gate: PREVENT Replaces the Old PCE Score

For primary prevention, the 2026 guideline uses the PREVENT equations rather than the older pooled cohort equations, or PCE. PREVENT uses age, sex, total cholesterol, HDL-C, systolic blood pressure, antihypertensive treatment, diabetes status, smoking status, estimated glomerular filtration rate, and body mass index. Optional inputs include HbA1c, urine albumin-to-creatinine ratio, and zip-code-based social deprivation index. Race is not included. [1]

PREVENT also changes the scale people are used to seeing. The guideline describes 10-year PREVENT risk as low under 3%, borderline from 3% to under 5%, intermediate from 5% to under 10%, and high at 10% or higher. A moderate-intensity statin is a Class 1 recommendation when 10-year PREVENT risk is 5% or higher. [1]

That 5% number is easy to misread if you remember the older 7.5% threshold. PREVENT generally produces lower 10-year risk estimates than PCE for the same person. The guideline’s crosswalk indicates that a profile scoring 7.5% with PCE often lands around 4% with PREVENT, so the lower threshold is not simply a more aggressive version of the old cut point. [1]

Class 1 Versus Class 2 Is the Difference Between “Recommended” and “May Be Considered”

The new guideline is easiest to apply if you keep the recommendation class visible. Class 1 means the guideline recommends the treatment. Class 2 means the treatment may be considered after a clinician-patient discussion. Those are not the same box.

The Class 2 pathway is the most important new doorway for many younger adults. For ages 30-59, the guideline says statin therapy may be considered when 10-year PREVENT risk is 3% to under 5% and the person also has either a 30-year PREVENT risk of at least 10% and/or LDL-C from 160 to 189 mg/dL. [1]

A hypothetical 34-year-old with a low short-term risk but a high long-term risk is exactly the kind of person this pathway is trying not to miss. The short-term number may look reassuring because age heavily drives 10-year risk, while the 30-year number can show a very different lifetime prevention problem. That does not make the 30-year estimate a verdict; it makes it a reason to have a more specific discussion than “you’re too young to worry about this.”

How to Check Yourself Before the Appointment

You do not need to diagnose yourself, but you can arrive with the right facts in the right order. The order matters because it prevents a common mistake: running a calculator first and missing an automatic indication.

1. Confirm whether you already have ASCVD. If yes, you are in secondary prevention, not the usual primary-prevention calculator pathway.
2. Find your LDL-C. If it is 190 mg/dL or higher, the guideline treats that as a risk-independent statin indication.
3. Check for diabetes, CKD stage 3 or higher, and HIV, and note your age. Diabetes and HIV criteria are age-specific in the guideline.
4. If no automatic indication applies, gather the PREVENT inputs: age, sex, total cholesterol, HDL-C, systolic blood pressure, blood-pressure medication use, diabetes status, smoking status, eGFR, and BMI.
5. For ages 30-59, look at both the 10-year and 30-year PREVENT estimates, and check whether LDL-C is 160-189 mg/dL.
6. Translate the result into the guideline class: 5% or higher 10-year PREVENT risk is Class 1; 3% to under 5% plus the younger-adult long-term-risk or LDL-C pathway is Class 2.

For many people, the answer after this check will be one of three things: recommended, may be considered, or not automatically eligible from the information available. The third answer does not mean “no risk.” It means the guideline criteria listed here have not, by themselves, placed the person into a statin recommendation group.

What Changed From 2018

The change from 2018 is not just that “more people qualify.” Three moving parts changed at the same time: the risk calculator changed from PCE to PREVENT, the Class 1 10-year risk threshold became 5% using PREVENT, and adults ages 30-59 gained a Class 2 pathway based on borderline 10-year risk plus 30-year risk and/or LDL-C 160-189 mg/dL. [1]

That is why population-impact studies can look contradictory if the recommendation class is left out. In an NHANES-based analysis by Diao and colleagues, applying the Class 1 threshold alone meant 3.0 million fewer U.S. adults qualified. Applying the broader Class 2 threshold meant 20.8 million more people qualified. [2]

So a headline saying the new guideline expands statins is directionally fair only if it includes the reason: the expansion comes from the lower PREVENT-based threshold and the added Class 2 pathway, not because PREVENT itself makes everyone look riskier. PREVENT often does the opposite for 10-year estimates.

How Many People Qualify Under the New Guideline?

One 2026 population estimate reported by Michigan Medicine found that 56.5% of U.S. adults ages 30-79 now qualify for statins under the new guidelines, or about 87.5 million people. The same analysis estimated 21.5 million newly eligible adults. [3]

Age does much of the work. The Michigan Medicine analysis reported eligibility of about 10% among people in their 30s, about 40% in their 40s, about 60% in their 50s, about 85% in their 60s, and 93.5% in their 70s. [3]

A separate Duke/Elsevier analysis focused on adults ages 40-75 found eligibility rising from 39.8% under the 2018 guideline to 54.3% under the 2026 guideline, adding 11.2 million eligible people in that age range. [4]

Those estimates answer a policy question, not an individual one. For an individual patient, the same guideline can mean automatic qualification, a Class 1 PREVENT-based recommendation, a Class 2 discussion, or no automatic eligibility from the available criteria.

The Equity Tension Is Real

Removing race from PREVENT is a major methodological change, and it produces a difficult practical tension. In the Diao analysis, Black adults lost Class 1 eligibility by 4.3 percentage points, compared with losses of 1.5 percentage points among White adults, 1.1 percentage points among Hispanic adults, and 0.9 percentage points among Asian adults. [2]

That finding can sit alongside the broader expansion and still be true. Class 1 eligibility can shrink for some groups because PREVENT corrects overestimation in the old PCE framework, while Class 2 eligibility can expand overall because the guideline added the borderline-risk, long-term-risk pathway.

This is where flattening the guideline into “millions more qualify” loses important information. A patient who loses Class 1 eligibility may still deserve a careful risk discussion. A patient newly entering Class 2 should also understand that “may be considered” is not the same as “the guideline says you definitely should take one.”

Younger Adults Are Newly Visible, but Often Still Untreated

The new 30-year pathway gives younger adults a clearer way into the statin conversation. That is useful because a 10-year risk score can make a person in their 30s look low risk even when their long-term risk is not reassuring.

But eligibility on paper and treatment in real life are different things. In a 2024 NHANES analysis of U.S. adults ages 20-39 with a Class 1 statin indication, fewer than 25% had ever been told by a clinician to take cholesterol medication. [5]

That treatment gap is a practical warning. A younger adult with LDL-C of 190 mg/dL or higher, or another clear indication, should not assume that being young makes the finding irrelevant. The point is not to turn every borderline lab into a prescription; it is to stop missing the people whose risk is already high enough to meet guideline criteria.

What the Guideline Does Not Decide for You

A statin eligibility box is not the whole treatment plan. Once eligibility is clear, the next decisions include statin intensity, expected LDL-C lowering, other risk enhancers, possible side effects, drug interactions, pregnancy considerations, and whether the person can or wants to take a daily medication.

Some people also need additional LDL-C lowering despite statin therapy, and some cannot tolerate statins well enough to use them as planned. In those situations, clinicians may discuss non-statin options; for example, some patients compare emerging oral PCSK9-pathway options such as enlicitide eligibility criteria or practical issues such as enlicitide cost comparisons when statins alone are not enough or not tolerated.

The 30-year risk pathway also deserves some humility. It is useful for making long-term risk visible in adults ages 30-59, but its evidence base is less independently validated than the 10-year pathway. That does not make it unusable; it means it should be treated as a discussion tool rather than a crystal ball.

A Plain-English Readout

You probably qualify under the 2026 guideline if you already have ASCVD, LDL-C of 190 mg/dL or higher, diabetes at ages 40-75, CKD stage 3 or higher, HIV at ages 40-75, or a 10-year PREVENT risk of at least 5%.

You may be in the “consider a statin” group if you are 30-59, your 10-year PREVENT risk is 3% to under 5%, and you also have a 30-year PREVENT risk of at least 10% and/or LDL-C from 160 to 189 mg/dL.

You are not automatically eligible from the information here if none of those conditions applies and your PREVENT risk does not cross the relevant threshold. That still leaves room for a clinician to review risk enhancers, family history, preferences, tolerability, and whether more testing would clarify the decision.

The 2026 rules do expand statin eligibility overall, especially through the lower PREVENT-based Class 1 threshold and the new 30-year Class 2 pathway. For one person sitting with one lab report, though, the answer still depends on age, automatic indications, and whether the result is “recommended” or “may be considered.”

References

1. 2026 ACC/AHA Dyslipidemia Guideline — Circulation, March 13, 2026.
2. Statin Recommendations among US Adults with the 2026 Dyslipidemia Guidelines — arXiv, May 2026.
3. More than half of U.S. adults now qualify for statins under new guidelines — Michigan Medicine, July 2026.
4. Changes in statin therapy eligibility under the 2026 versus 2018 dyslipidemia guidelines — Duke/Elsevier, 2026.
5. Guideline recommended statin eligibility and use among U.S. adults ages 20 to 39 years — American Journal of Preventive Cardiology, 2024.